GC Rieber VivoMega to make significant investment in facility expansion
GC Rieber VivoMega has announced a five-year $75 million investment plan to build a new facility at its manufacturing campus. The new facility will enable the company to more than double the output of its high-end triglyceride form of omega-3s EPA and DHA.
Photo © iStockphoto.com/ evemilla
GC Rieber VivoMega (Norway) has announced a five-year $75 million investment plan to build a new facility at its manufacturing campus, with an anticipated completion date of early 2024. The new facility will enable the company to more than double the output of its high-end triglyceride form of omega-3s EPA and DHA.
“This investment is part of GC Rieber VivoMega’s continual commitment to develop the needed facilities for the increased capacity and production of our industry leading omega-3 oils,” said Jan Roger Bjerkestrand, managing director of GC Rieber VivoMega, in a press release. “To minimize our eco-footprint, we will be leveraging much of the existing infrastructure, including docks, tanks, laboratories, and energy to provide the same high-quality product that our customers are asking for.”
By the summer of 2022, GC Rieber VivoMega will complete the construction of a 32,000-metric ton tank park and updated technology platform in their existing manufacturing plants. The tank park enables the company to adjust to current supply chain challenges and is a key strategic asset to supporting the new expansion. Therefore, the new facility is also being designed with added flexibility to support future strategic growth areas in omega-3 high-end concentrates.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.
